Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Lung Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Lung Cancer
    Gefitinib Approved in EU for Locally Advanced, Metastatic NSCLC - (DGNews)
    TopAbstracts in Lung Cancer 06/24/2009 - (DGNews)
    TopAbstracts in Lung Cancer 06/10/2009 - (DGNews)
    Prophylactic Cranial Irradiation Has No Impact on Overall Survival in Patients With NSCLC Brain Metastases: Presented at ASCO - (DGDispatch)
    Vandetanib Plus Docetaxel Combination Prolongs Progression-Free Survival in Patients With Non-Small-Cell Lung Cancer: Presented at ASCO - (DGDispatch)

    News archive

     Recent webcasts/CME - Lung Cancer
  • Latest Data From Chicago Provide New Insight Into the Evolving Role of Cytotoxic and Targeted Therapies in Early-Stage NSCLC
  • Silica-Related Lung Disease: It's Still Here

    Webcasts/CME archive

     Recent cases - Lung Cancer
      Diffuse Interstitial Lung Disease Related to Peribronchiolar Metaplasia
      Isolated Pancreatic Metastases from a Bronchogenic Small Cell Carcinoma
      High-Resolution Computed Tomography Illustrating Pulmonary Lymphangitic Carcinomatosis in a Patient with Advanced Pancreatic Cancer: A Case Report
      Mesothelioma in an HIV/AIDS Patient Without History of Asbestos Exposure: Possible Role For Immunosuppression in Mesothelioma: A Case Report
      Pulmonary Lymphoma Mimicking Metastases: A Case Report

      Cases archive
        




      my personal edition > lung cancer > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Significant Clinical Benefit Seen with Gefitinib in Advanced Non-Small Cell Lung Cancer: Presented at WCLC

      By Patrice Olson

      VANCOUVER, BC -- August 21, 2003 -- Gefitinib (Iressa, ZD18) is showing significant clinical benefit for the treatment of advanced non-small cell lung cancer (NSCLC), US investigators report.

      Dr. Pasi Janne, Dana Farber Cancer Institute, Boston, Massachusetts, and colleagues recruited patients with stage IIIB/IV NSCLC who were ineligible for other systemic therapies. Patients were then enrolled in the compassionate use program for gefitinib treatment.

      Patients previously had a median of two chemotherapy regimens, and had a median performance status (PS) of 1. Findings were presented during the 10th World Conference on Lung Cancer, held here Aug. 10th-14th.

      Out of 172 patients who received treatment with gefitinib, 11 died shortly after from their disease. Another seven patients achieved a partial response. All responders were women, and all had adenocarcinoma, the authors noted, while four out of the seven responders had bronchioalveolar cell carcinoma. Disease stabilized in another 60 patient, or 35% of the group overall.

      Median survival for all patients was 4.5 months, and 29% of the group were still alive at 1 year. Out of 156 patients who were evaluable for toxicity, 4.5% developed grade 3 toxicity, and 0.6% patient developed grade 4 toxicity. T the authors noted that women responded better to gefitinib than men, with a longer median overall survival of 5 months, compared to 4 months for men.

      Approximately 28% of women and 18% of men who were treated with gefitinib were alive at 1 year.

      The authors also observed that patients who achieved either a partial response or disease stabilization were more likely to develop a skin rash, and that patients were more likely to survive if they developed any grade of skin toxicity compared to patients who did not develop skin toxicity.


      [Study title: Clinical benefits in patients with advanced NSCLC treated with gefitinib (Iressa, ZD 1839) in the compassionate use program. Abstract 0-243]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send